Assessment of CD24 and NFIL3 expression in melanoma patients treated with immune c...
Assessment of BRAF mutations and their predictive value in patients with advanced ...
Beyond therapeutic boundaries in melanoma: unraveling biomarkers and strategies to...
Impact of epithelial-mesenchymal transition proteins in vemurafenib chemoresistant...
Exploring biomarkers associated with clinical outcomes in melanoma patients treate...
Immune-checkpoint inhibitors: immunophenotyping and clinical outcome to predict re...
RMEL3 long noncoding RNA as a modulator of the immune response in melanoma